Nagashree Seetharamu: Navigating Treatment Beyond 3 Years of Survival in Metastatic EGFR+ NSCLC

Nagashree Seetharamu, Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared a post on X/Twitter:

”Are people getting denials from insurance for treatment beyond 3 years of overall survival interval in metastatic setting (EFGR+ NSCLC) despite sending all the necessary documents?

Writing an appeal letter and trying to maintain professionalism.”

Source: Nagashree Seetharamu/X